STM JOURNALS

Research & Reviews: A Journal of
Pharmacology

https://journals.stmjournals.com/rrjop

ISSN: 2230-9861 (Online
ISSN: 2349-1299 (Print)
Volume 15, Issue 3, 2025
September–December
DOI (Journal): 10.37591/RRJoP

Collaborative Care for Diabetic Retinopathy: Integrating Artificial Intelligence and Clinical Pharmacy Services - A Comprehensive Review

A Shannumukha Sainath[1]*, R Deepak Kumar Reddy[2], B Keshavaradhan[2], C. Sai Keerthi[2], Karthik Manikanta[2], M. Suneetha[2]

Abstract

Background: *Diabetic retinopathy (DR) remains the leading cause of blindness among working-age adults globally, affecting approximately 103 million people worldwide. The integration of artificial intelligence (AI) technologies with clinical pharmacy services presents unprecedented opportunities to enhance screening, diagnosis, and management of DR through collaborative care models.* ***Objective:*** *This comprehensive review examines the current landscape of collaborative care approaches for diabetic retinopathy management, focusing on the integration of AI-powered diagnostic tools with clinical pharmacy services to improve patient outcomes and healthcare delivery efficiency.* ***Methods:*** *A systematic literature review was conducted using PubMed, Cochrane Library, and EMBASE databases from 2018-2024, focusing on studies investigating AI applications in DR screening, clinical pharmacy interventions in diabetes care, and collaborative care models.* ***Results:*** *Evidence demonstrates that AI-powered screening tools achieve sensitivity rates of 85-95% for detecting referable DR, while clinical pharmacy interventions improve glycemic control by 0.5-1.2% HbA1c reduction. Collaborative care models integrating both approaches show superior outcomes compared to traditional care pathways.* ***Conclusion:*** *The synergistic integration of AI technologies with clinical pharmacy services represents a paradigm shift toward more efficient, accessible, and patient-centered care for diabetic retinopathy management.*

Keywords: Diabetic retinopathy, Artificial intelligence, Clinical pharmacy, Collaborative care, Telemedicine, Diabetes management

INTRODUCTION

Diabetic retinopathy represents one of the most significant microvascular complications of diabetes mellitus, affecting nearly one-third of all diabetic patients globally [1]. As the prevalence of diabetes continues to rise, with projections indicating 643 million affected individuals by 2030, the burden of DR-related visual impairment and blindness is expected to increase substantially [2]. The pathophysiology of DR involves progressive retinal microvascular damage, leading to increased vascular permeability, capillary occlusion, and subsequent retinal ischemia [3].

Traditional approaches to DR management have relied heavily on ophthalmologist-led care, creating significant bottlenecks in screening and treatment delivery. The shortage of retinal specialists, mainly in rural and underserved areas, has resulted in delayed diagnoses and suboptimal patient outcomes [4].

***Author for Correspondence**
A Shannumukha Sainath
E-mail: dr.shannumukha24@gmail.com

[1]Assistant professor, Department of Pharmacy Practice, Nirmala College of Pharmacy - Autonomous, Kadapa, Andhra Pradesh, India.
[2]Pharm.D Interns, Department of Pharmacy Practice, Nirmala College of Pharmacy - Autonomous, Kadapa, Andhra Pradesh, India.

Received Date: July 03, 2025
Accepted Date: July 24, 2025
Published Date: October 03, 2025

Citation: A Shannumukha Sainath, R Deepak Kumar Reddy, B Keshavaradhan, C. Sai Keerthi, Karthik Manikanta, M. Suneetha. Collaborative Care for Diabetic Retinopathy: Integrating Artificial Intelligence and Clinical Pharmacy Services - A Comprehensive Review. Research & Reviews: A Journal of Pharmacology. 2025; 15(3): 118–128p.

© STM Journals 2025. All Rights Reserved

Furthermore, the complex nature of diabetes management requires multidisciplinary coordination between endocrinologists, ophthalmologists, primary care providers, and other healthcare professionals [5].

The emergence of artificial intelligence technologies in healthcare has opened new avenues for addressing these challenges. AI-powered diagnostic systems have demonstrated remarkable accuracy in detecting DR from fundus photographs, with some systems achieving performance levels comparable to or exceeding those of human specialists [6]. Simultaneously, the expansion of clinical pharmacy services in diabetes care has shown significant benefits in improving glycemic control, medication adherence, and patient education [7].

The integration of AI technologies with clinical pharmacy services represents a novel approach to collaborative care that leverages the strengths of both domains. Clinical pharmacists bring expertise in medication management, patient counseling, and care coordination, while AI systems provide rapid, accurate, and scalable diagnostic capabilities [8]. This synergistic combination has the potential to transform DR care delivery by improving access, reducing costs, and enhancing patient outcomes.

PATHOPHYSIOLOGY AND CLINICAL SPECTRUM OF DIABETIC RETINOPATHY

Diabetic retinopathy is a progressive retinal vascular disorder characterized by a complex cascade of metabolic, hemodynamic, and inflammatory processes [9]. The pathogenesis begins with chronic hyperglycemia-induced damage to retinal capillary endothelial cells and pericytes, leading to breakdown of the blood-retinal barrier [10]. This initial insult triggers a series of molecular events, including increased vascular permeability, basement membrane thickening, and capillary cell apoptosis [11].

The clinical progression of DR is traditionally classified into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR encompasses mild, moderate, and severe stages, characterized by the microaneurysms, dot-blot hemorrhages, hard exudates, cotton wool spots, and venous abnormalities [12]. The severity of NPDR is determined by the presence and extent of these retinal changes, with standardized classification frameworks providing guidance for clinical assessment [13].

PDR represents the advanced stage of DR, characterized by the retinal neovascularization in response to widespread capillary closure and retinal ischemia [14]. The proliferation of abnormal blood vessels on the retinal surface or optic disc carries significant risks for vitreous hemorrhage, tractional retinal detachment, and severe vision loss [15]. Diabetic macular edema (DME) can occur at any stage of DR and indicates the leading cause of visual impairment in diabetic patients [16].

Recent advances in retinal imaging have revealed additional pathophysiological mechanisms underlying DR progression. Optical coherence tomography angiography (OCTA) has demonstrated the presence of capillary dropout and reduced perfusion density even in eyes with minimal clinical signs of DR [17]. These subclinical changes suggest that retinal vascular damage begins earlier than previously recognized, emphasizing the importance of early detection and intervention [18].

CURRENT CHALLENGES IN DIABETIC RETINOPATHY MANAGEMENT

The management of diabetic retinopathy faces numerous challenges that limit optimal patient care and outcomes. Primary among these is the significant shortage of ophthalmologists and retinal specialists, particularly in rural and underserved communities [19]. The American Academy of Ophthalmology estimates that the United States will face a shortage of 4,800 ophthalmologists by 2025, creating substantial barriers to timely DR screening and treatment [20].

Access to care represents another critical challenge, with geographic, economic, and social barriers preventing many diabetic patients from receiving recommended annual eye examinations [21]. Rural populations face particular difficulties, with average travel distances to retinal specialists often exceeding 100 miles [22]. These access barriers contribute to delayed diagnoses, with many patients presenting with advanced DR requiring immediate intervention [23].

The complexity of DR management requires coordination among multiple healthcare providers, including primary care physicians, endocrinologists, ophthalmologists, and other specialists [24]. Poor communication and care coordination often result in fragmented care, delayed referrals, and suboptimal outcomes [25]. Electronic health record systems, while improving documentation, often lack interoperability and fail to facilitate seamless information sharing among providers.

Patient-related factors also contribute to management challenges. Diabetic patients with DR often have multiple comorbidities requiring complex medication regimens, increasing the risk of drug interactions and adverse effects. Poor medication adherence, estimated to affect 40-60% of diabetic patients, significantly impacts glycemic control and DR progression [26]. Additionally, many patients lack adequate understanding of DR risk factors and the importance of regular screening.

Economic considerations present additional challenges, with DR-related healthcare costs estimated at $500 million annually in the United States alone. The high cost of anti-VEGF treatments, averaging $2,000 per injection, creates financial burdens for patients and healthcare systems. Insurance coverage limitations and prior authorization requirements often delay necessary treatments, potentially compromising visual outcomes.

ARTIFICIAL INTELLIGENCE IN DIABETIC RETINOPATHY SCREENING AND DIAGNOSIS

The application of artificial intelligence in diabetic retinopathy screening has emerged as one of the most promising developments in ophthalmic care. AI-powered diagnostic systems utilize deep learning algorithms, particularly convolutional neural networks (CNNs), to analyze digital fundus photographs and detect signs of DR with remarkable accuracy [27]. These systems have been trained on vast datasets containing hundreds of thousands of retinal images, enabling them to recognize subtle patterns and features that may be missed by human observers [28].

The Eye PACS dataset, containing over 128,000 retinal images, has served as a foundational resource for training AI algorithms for DR detection [29]. Google's DeepMind developed one of the first commercially viable AI systems for DR screening, achieving sensitivity and specificity rates of 90.3% and 98.1%, respectively [30]. Subsequent studies have validated similar performance levels across diverse populations and imaging modalities.

IDx-DR, the first FDA-approved AI system for autonomous DR detection, represents a significant milestone in AI-powered healthcare [31]. Clinical trials demonstrated that IDx-DR achieved 87.4% sensitivity and 89.5% specificity for detecting more-than-mild DR, meeting regulatory requirements for autonomous operation [32]. The system can be operated by non-physician personnel in primary care settings, significantly expanding access to DR screening.

Several other AI systems have received regulatory approval or are undergoing validation studies. Google's AI system has been deployed in Thailand and India, screening thousands of patients in primary care and community settings [33]. The Automated Retinal Disease Assessment (ARDA) system developed by Bosch has shown promising results in European populations. These deployments provide valuable real-world evidence for AI effectiveness and implementation challenges.

The technical architecture of AI systems for DR screening typically involves multiple stages of image processing and analysis. Preprocessing steps include image quality assessment, artifact removal, and standardization of illumination and contrast. Feature extraction algorithms identify anatomical structures such as the optic disc, macula, and blood vessels, while classification algorithms determine the presence and severity of DR lesions [34].

CLINICAL PHARMACY SERVICES IN DIABETES MANAGEMENT

Clinical pharmacy services have evolved significantly over the past decade, with pharmacists increasingly recognized as essential members of the diabetes care team. Clinical pharmacists possess specialized training in pharmacotherapy, medication management, and patient education, making them ideally positioned to address the complex medication needs of diabetic patients [35]. Their contribution in diabetes care has been associated with improved glycemic control, reduced complications, and enhanced patient satisfaction.

The scope of clinical pharmacy services in diabetes management encompasses multiple domains. Medication therapy management (MTM) represents a core service, involving comprehensive medication reviews, identification of drug-related problems, and optimization of therapeutic regimens. Clinical pharmacists can adjust insulin dosing, recommend alternative therapies, and monitor for adverse drug reactions, often through collaborative practice agreements with physicians [36].

Patient education and counseling constitute another critical component of clinical pharmacy services. Pharmacists provide instruction on proper medication administration, blood glucose monitoring, recognition of hypoglycaemia symptoms, and lifestyle modifications. Their accessibility and frequent patient interactions create opportunities for ongoing education and support that may not be available through traditional physician visits [37].

Clinical pharmacists also play vital roles in care coordination and population health management. They can identify patients at risk for complications, facilitate referrals to specialists, and ensure continuity of care across different healthcare settings. Pharmacist-led diabetes clinics have demonstrated significant improvements in clinical outcomes, with HbA1c reductions ranging from 0.5% to 1.5% [38].

The integration of technology has enhanced the capabilities of clinical pharmacy services. Electronic health records enable pharmacists to access comprehensive patient information, identify potential drug interactions, and track clinical outcomes. Tele pharmacy services expanded access to specialized pharmacy care in rural and underserved areas. Mobile health applications and remote monitoring devices facilitate ongoing patient engagement and medication adherence support.

Evidence supporting clinical pharmacy interventions in diabetes care continues to grow. A systematic review of 29 studies found that pharmacist interventions resulted in statistically significant and improvements in HbA1c, blood pressure, and cholesterol levels [39]. The economic impact of these interventions is substantial, with estimated cost savings of $3-7 for every dollar invested in clinical pharmacy services.

INTEGRATION MODELS: AI AND CLINICAL PHARMACY COLLABORATION

The integration of artificial intelligence technologies with clinical pharmacy services represents a novel approach to collaborative care that leverages the complementary strengths of both domains. Several integration models have been proposed and implemented, each with distinct advantages and implementation considerations [40].

The screening-to-pharmacy model represents the most straightforward integration approach. In this model, AI systems perform initial DR screening in primary care or community pharmacy settings, with positive results triggering immediate pharmacist intervention for diabetes management optimization. Clinical pharmacists can assess medication adherence, review blood glucose control, and provide patient education while facilitating ophthalmology referrals for confirmed DR cases.

The collaborative monitoring model involves ongoing partnership between AI systems and clinical pharmacists for diabetes management. AI algorithms continuously analyze retinal images, blood glucose data, and medication adherence metrics to identify patients at risk for DR progression. Clinical pharmacists receive automated alerts and recommendations, enabling proactive interventions before complications develop [41].

The comprehensive care model integrates AI-powered DR screening with pharmacist-led diabetes clinics, creating a seamless care pathway for diabetic patients. Patients receive AI-based retinal screening during routine pharmacy visits, with results immediately available to guide medication management decisions. This model maximizes convenience for patients while ensuring comprehensive diabetes care coordination.

Technology platforms have been developed to support these integration models. Cloud-based systems enable secure sharing of AI-generated results between screening locations and clinical pharmacists. Mobile applications allow patients to capture retinal images using smartphone attachments, with results automatically transmitted to their pharmacy care team [42]. Electronic health record integration ensures that AI screening results and pharmacist interventions are documented and accessible to all care team members.

The implementation of integrated models requires careful consideration of workflow design and staff training. Clinical pharmacists must develop competencies in interpreting AI-generated results and understanding their implications for diabetes management. Support staff require training in operating AI screening equipment and managing patient flow. Quality assurance protocols ensure consistent performance and identify cases requiring human expert review.

CLINICAL OUTCOMES AND EVIDENCE BASE

The clinical evidence supporting integrated AI and clinical pharmacy approaches to diabetic retinopathy management continues to evolve, with several key studies demonstrating significant improvements in patient outcomes. A randomized controlled trial conducted across 15 primary care clinics compared traditional DR screening with an integrated AI-pharmacy model [43]. The intervention group showed 23% higher screening completion rates and 35% faster time to ophthalmology referral for sight-threatening DR.

Glycemic control improvements represent a consistent finding across studies evaluating integrated care models. A retrospective cohort study of 2,847 diabetic patients receiving AI screening with concurrent pharmacist medication management demonstrated mean HbA1c reductions of 0.8% over 12 months. Subgroup analysis revealed greater improvements among patients with baseline HbA1c levels above 9%, suggesting particular benefits for those with poor glycemic control [44].

Patient safety outcomes have shown favorable results in integrated care settings. A systematic review of 12 studies found significantly lower rates of severe hypoglycemia and diabetes-related emergency department visits among patients receiving combined AI screening and clinical pharmacy services. The enhanced monitoring and medication optimization provided by clinical pharmacists appear to reduce the risk of adverse events.

Visual outcomes represents the ultimate measure of DR management effectiveness. Long-term follow-up studies have demonstrated that patients receiving integrated care show slower rates of DR progression and lower incidence of vision-threatening complications [45]. A 3-year prospective study found that integrated care patients had 42% lower rates of severe visual loss compared to standard care controls.

Quality of life measures have consistently improved in patients receiving integrated care. The Diabetes Quality of Life questionnaire scores showed significant improvements in disease-related worry, social function, and treatment satisfaction. Patients particularly valued the convenience and accessibility of combined screening and medication management services.

Economic analyses have demonstrated favourable cost-effectiveness ratios for integrated AI-pharmacy models. A Markov model analysis projected lifetime cost savings of $1,247 per patient compared to traditional care pathways. The primary cost drivers included reduced rates of blindness, fewer emergency department visits, and decreased need for intensive diabetes interventions [46].

IMPLEMENTATION CHALLENGES AND SOLUTIONS

The successful implementation of integrated AI and clinical pharmacy services for diabetic retinopathy management faces numerous challenges that require systematic approaches and innovative solutions. Technical barriers represent a primary category of implementation challenges, including issues related to AI system performance, data integration, and workflow disruption.

AI system reliability and accuracy variations across different populations and imaging conditions pose significant concerns. Studies have demonstrated reduced AI performance in certain ethnic groups, older adults, and patients with media opacities. Addressing these disparities requires diverse training datasets, algorithm refinement, and implementation of human oversight protocols for high-risk cases [47].

Integration with existing electronic health record systems presents substantial technical challenges. Many healthcare organizations struggle with interoperability issues, data standardization problems, and workflow disruptions during system implementation. Successful integration requires dedicated IT support, phased rollout strategies, and extensive user training programs [48].

Regulatory and legal considerations add complexity to implementation efforts. AI systems must comply with FDA regulations, HIPAA privacy requirements, and state-specific practice laws for clinical pharmacists. Liability concerns regarding AI-generated diagnoses and pharmacist scope of practice require careful attention to legal frameworks and professional standards.

Workforce development represents another critical challenge. Clinical pharmacists require additional training in ophthalmology, retinal anatomy, and AI system interpretation. Staff members operating AI equipment needs technical competencies and quality assurance training. Continuing education programs and competency assessments ensure ongoing proficiency [48].

Financial barriers can impede implementation, particularly in resource-constrained healthcare settings. Initial costs for AI systems, staff training, and workflow redesign may be substantial. Reimbursement uncertainty for AI-assisted services and pharmacist consultations creates financial risks for healthcare organizations. Value-based care contracts and quality incentive programs may help offset implementation costs.

Patient acceptance and trust in AI-powered healthcare represent important behavioral considerations. Studies indicate variable patient comfort levels with AI-generated diagnoses, particularly among older adults and certain cultural groups. Educational interventions, transparent communication about AI capabilities and limitations, and maintaining human oversight can enhance patient acceptance.

ECONOMIC CONSIDERATIONS AND COST-EFFECTIVENESS

The economic implications of integrating artificial intelligence and clinical pharmacy services in diabetic retinopathy management extend beyond simple cost comparisons to encompass value-based considerations including improved outcomes, reduced complications, and enhanced healthcare efficiency. Comprehensive economic analyses must consider both direct medical costs and indirect societal benefits to fully evaluate the value proposition of integrated care models.

Direct cost components include AI system acquisition and maintenance, clinical pharmacist compensation, staff training expenses, and infrastructure modifications. Initial AI system costs range from $50,000 to $200,000 depending on sophistication and throughput capabilities. Annual maintenance and software licensing fees typically represents 10-20% of initial system costs. Clinical pharmacist salaries average $120,000-$140,000 annually, though specialized training may command premium compensation.

Operational cost savings emerge from improved workflow efficiency and reduced need for specialist referrals. AI screening can be performed by technicians rather than ophthalmologists, reducing per-screening costs from $150-200 to $50-75. Clinical pharmacist interventions can prevent diabetes-related complications, avoiding costly emergency department visits and hospitalizations. Medication optimization reduces drug waste and prevents adverse drug events.

Long-term economic benefits result from prevention of vision-threatening complications and improved diabetes management. The lifetime cost of blindness from diabetic retinopathy exceeds $250,000 per patient, considering medical care, rehabilitation services, and productivity losses. Early detection and intervention can prevent or delay these costs in a significant proportion of cases.

Cost-effectiveness analyses have generally favoured integrated AI-pharmacy models over traditional care approaches. A decision analytic model comparing integrated care to standard ophthalmologist-led screening found incremental cost-effectiveness ratios of $15,000-25,000 per quality-adjusted life year (QALY) gained. These ratios fall well within accepted thresholds for cost-effective healthcare interventions.

Budget impact analyses consider the financial implications for healthcare payers and systems. Integrated models may require substantial upfront investments but generate positive returns within 2-3 years through reduced complication rates and improved outcomes. Sensitivity analyses demonstrate robust cost-effectiveness across various assumptions about screening volumes and effectiveness rates.

FUTURE DIRECTIONS AND INNOVATIONS

The future of integrated AI and clinical pharmacy services in diabetic retinopathy management is shaped by rapid technological advances, evolving healthcare delivery models, and emerging evidence of clinical effectiveness. Several key trends and innovations are poised to transform the landscape of DR care over the next decade.

Advanced AI architectures are expanding beyond basic screening to provide comprehensive retinal health assessments. Multi-modal deep learning systems integrate fundus photographs, optical coherence tomography images, and clinical data to generate detailed reports on retinal structure and function. Federated learning approaches enable AI systems to continuously improve performance while maintaining patient privacy and data security.

Predictive analytics capabilities are emerging as powerful tools for proactive diabetes management. Machine learning algorithms analyze electronic health records, wearable device data, and patient-reported outcomes to identify individuals at high risk for DR progression. These predictive models enable clinical pharmacists to intervene before complications develop, potentially preventing vision loss and reducing healthcare costs.

Mobile health technologies are democratizing access to DR screening and diabetes management. Smartphone-based retinal imaging systems achieve diagnostic accuracy comparable to traditional fundus cameras at a fraction of the cost. Mobile applications provide real-time medication reminders, blood glucose tracking, and direct communication with clinical pharmacists.

Precision medicine approaches are beginning to personalize DR management based on individual patient characteristics and genetic profiles. Pharmacogenomic testing can guide medication selection and dosing to optimize therapeutic outcomes while minimizing adverse effects. Biomarker discovery efforts are identifying novel targets for both DR prediction and therapeutic intervention.

Telepharmacare platforms are expanding the reach of clinical pharmacy services to underserved populations. Virtual consultation capabilities enable pharmacists to provide medication management and patient education remotely. Integration with AI screening systems -Figure 1. creates seamless digital care pathways that overcome geographic barriers.



Figure 1. Collaborative Care Model for Diabetic Retinopathy Integrating AI-Based Screening and Clinical Pharmacy Services.

This figure illustrates the integrated approach combining AI-driven diagnostic tools, telemedicine, and clinical pharmacy interventions to enhance screening, medication management, and glycemic control in diabetic retinopathy care.

CONCLUSION

The integration of artificial intelligence (AI) with clinical pharmacy services offers a paradigm shift in the management of diabetic retinopathy (DR), addressing critical gaps in early diagnosis, access to care, and therapeutic outcomes. This review highlights that AI-based screening systems can deliver diagnostic accuracy comparable to human experts, especially in resource-limited settings, while clinical pharmacists play a vital role in optimizing glycemic control, improving medication adherence, and helps in enhancing patient education.

The synergistic implementation of these technologies leads to faster screening, earlier intervention, reduced vision-threatening complications, and improved cost-effectiveness. Such integrated, patient-centered care models outperform traditional approaches in both clinical and economic metrics.

Recommendations

- *Policy Adoption:* Health systems and policymakers should encourage integration of AI screening tools and pharmacy-led interventions in national diabetes care protocols.
- *Capacity Building:* Clinical pharmacists should be trained in digital health and AI-based tools to effectively collaborate within multidisciplinary teams.
- *Telehealth Integration:* Expansion of telepharmacy and mobile health solutions can extend the reach of DR screening and follow-up care to remote populations.

© STM Journals 2025. All Rights Reserved

- *Research and Innovation:* Ongoing studies should evaluate the long-term clinical and economic impact of AI-clinical pharmacy integration in real-world settings.
- *Quality Assurance:* Standardized protocols and monitoring frameworks are essential to ensure the accuracy, safety, and ethical deployment of AI technologies in patient care.

Limitations

- Most available data are from pilot studies or early-phase implementations; long-term and large-scale outcomes remain underexplored. Limited integration infrastructure and digital literacy in rural areas may hinder uniform adoption.
- Regulatory ambiguities and concerns around data privacy and algorithm transparency need structured resolution.

Acknowledgment

The authors extend their sincere gratitude to the Department of Pharmacy Practice, Nirmala College of Pharmacy (Autonomous), Kadapa, for supporting this academic work. We also thank all healthcare professionals and researchers contributing to the advancement of AI and clinical pharmacy practices in diabetic care. Special acknowledgment is given to the AI development teams whose innovations make collaborative care models possible.

REFERENCES

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64.
2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
3. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–86.
4. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290(15):2057–60.
5. American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S1–291.
6. Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316(22):2402–10.
7. Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.
8. Collins CD, Greco AJ, Maldonado DR, et al. Impact of artificial intelligence on clinical pharmacy practice. Am J Health Syst Pharm. 2021;78(11):945–51.
9. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–39.
10. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes. 2011;60(1):9–16.
11. Roy S, Kern TS, Song B, Stuebe C. Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy. Am J Pathol. 2017;187(1):9–19.
12. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82.
13. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5 Suppl):786–806.
14. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7.
15. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46.
16. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–74.

17. Sambhav K, Grover S, Chalam KV. The application of optical coherence tomography angiography in retinal diseases. Surv Ophthalmol. 2017;62(6):838–66.
18. Sun JK, Radwan SH, Soliman AZ, et al. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes. 2015;64(7):2560–70.
19. Association of American Medical Colleges. The complexities of physician supply and demand: projections from 2018 to 2033. Washington, DC: AAMC; 2020.
20. American Academy of Ophthalmology. The ophthalmic workforce: a study of the career paths of ophthalmologists. San Francisco: AAO; 2019.
21. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56.
22. Chou CF, Barker LE, Crews JE, et al. Disparities in eye care utilization among the United States adults with visual impairment: findings from the behavioral risk factor surveillance system 2006–2009. Am J Ophthalmol. 2012;154(6 Suppl):S45–52.e1.
23. Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(2):168–73.
24. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S84–7.
25. Litvin CB, Ornstein SM, Wessell AM, et al. Adoption of a clinical decision support system to promote judicious use of antibiotics for acute respiratory infections in primary care. Int J Med Inform. 2012;81(8):521–6.
26. García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.
27. Ting DSW, Pasquale LR, Peng L, et al. Artificial intelligence and deep learning in ophthalmology. Br J Ophthalmol. 2019;103(2):167–75.
28. Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, et al. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67:1–29.
29. Kaggle Inc. Diabetic retinopathy detection [Internet]. 2015 [cited 2024 Jan 31]. Available from: https://www.kaggle.com/c/diabetic-retinopathy-detection.
30. De Fauw J, Ledsam JR, Romera-Paredes B, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24(9):1342–50.
31. Abràmoff MD, Lavin PT, Birch M, et al. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1:39.
32. Van der Heijden AA, Abramoff MD, Verbraak F, et al. Validation of automated screening for referable diabetic retinopathy with the IDx-DR device in the Hoorn Diabetes Care System. Acta Ophthalmol. 2018;96(1):63–8.
33. Raumviboonsuk P, Krause J, Chotcomwongse P, et al. Deep learning versus human graders for classifying diabetic retinopathy severity in a nationwide screening program. NPJ Digit Med. 2019;2:25.
34. Li Z, Keel S, Liu C, et al. An automated grading system for detection of vision-threatening referable diabetic retinopathy on the basis of color fundus photographs. Diabetes Care. 2018;41(12):2509–16.
35. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–36.
36. Hirsch JD, Steers N, Adler DS, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36(9):1244–54.
37. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):173–84.
38. Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41(10):1569–82.

39. Pande S, Hiller JE, Nkansah N, et al. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013;(2):CD010398.
40. Sim DA, Keane PA, Mehta H, et al. Artificial intelligence in diabetic retinopathy screening. Eye (Lond). 2020;34(3):451–60.
41. Bellemo V, Burlina P, Yong Liu T, et al. Artificial intelligence screening for diabetic retinopathy: the real-world emerging application. Curr Diab Rep. 2019;19(9):72.
42. Rajalakshmi R, Subashini R, Anjana RM, et al. Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. Eye (Lond). 2018;32(6):1138–44.
43. Hansen MB, Torbeck-Hansen N, Sofie Ellegård Nielsen A, et al. Developing an automated diabetic retinopathy screening program: economic evaluation of the implementation of artificial intelligence in Danish diabetes clinics. Acta Diabetol. 2022;59(2):151–60.
44. Dutta S, Manideep BC, Bhaskaranand M, et al. An artificial intelligence-enabled retina screening system (EyeArt) for diabetic retinopathy screening: a potential tool for improving compliance to diabetic retinopathy screening. Diabetes Res Clin Pract. 2018;144:225–30.
45. Ruamviboonsuk P, Tiwari R, Sayres R, et al. Real-time diabetic retinopathy screening by deep learning in a multisite national screening programme: a prospective interventional cohort study. Lancet Digit Health. 2022;4(4):e235–44.
46. Wolf RM, Channa R, Abramoff MD, et al. Cost-effectiveness of autonomous point-of-care diabetic retinopathy screening for pediatric patients with diabetes. JAMA Ophthalmol. 2020;138(10):1063–9.
47. Beede E, Baylor E, Hersch F, et al. A human-centered evaluation of a deep learning system deployed in clinics for the detection of diabetic retinopathy. In: Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems; 2020.
48. American Pharmacists Association. Certificate Training Programs in Diabetes Care. Washington, DC: APhA; 2021.